← Back to all trials
Active Not Recruiting
NCT01763554
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
Conditions: Neuroendocrine Tumors, NET
Sex: All
Ages: 14 Years – 90 Years
Healthy volunteers: No
Enrollment: 115
Sponsor: AHS Cancer Control Alberta
Location: Cross Cancer Institute Edmonton Alberta
Summary
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Eligibility Criteria
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
Source: ClinicalTrials.gov (NCT01763554). StuddyBuddy aggregates publicly available trial information.
